FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802899563> ?p ?o ?g. }

• W2802899563 endingPage "1956" @default.
• W2802899563 startingPage "1949" @default.
• W2802899563 abstract "Purpose Neoadjuvant chemotherapy followed by radical cystectomy (RC) is a standard of care for the management of muscle-invasive bladder cancer (MIBC). Dose-dense cisplatin-based regimens have yielded favorable outcomes compared with standard-dose chemotherapy, yet the optimal neoadjuvant regimen remains undefined. We assessed the efficacy and tolerability of six cycles of neoadjuvant dose-dense gemcitabine and cisplatin (ddGC) in patients with MIBC. Patients and Methods In this prospective, multicenter phase II study, patients received ddGC (gemcitabine 2,500 mg/m 2 on day 1 and cisplatin 35 mg/m 2 on days 1 and 2) every 2 weeks for 6 cycles followed by RC. The primary end point was pathologic downstaging to non–muscle-invasive disease (< pT2N0). Patients who did not undergo RC were deemed nonresponders. Pretreatment tumors underwent next-generation sequencing to identify predictors of chemosensitivity. Results Forty-nine patients were enrolled from three institutions. The primary end point was met, with 57% of 46 evaluable patients downstaged to < pT2N0. Pathologic response correlated with improved recurrence-free survival and overall survival. Nineteen patients (39%) required toxicity-related dose modifications. Sixty-seven percent of patients completed all six planned cycles. No patient failed to undergo RC as a result of chemotherapy-associated toxicities. The most frequent treatment-related toxicity was anemia (12%; grade 3). The presence of a presumed deleterious DNA damage response (DDR) gene alteration was associated with chemosensitivity (positive predictive value for < pT2N0 [89%]). No patient with a deleterious DDR gene alteration has experienced recurrence at a median follow-up of 2 years. Conclusion Six cycles of ddGC is an active, well-tolerated neoadjuvant regimen for the treatment of patients with MIBC. The presence of a putative deleterious DDR gene alteration in pretreatment tumor tissue strongly predicted for chemosensitivity, durable response, and superior long-term survival." @default.
• W2802899563 created "2018-05-17" @default.
• W2802899563 creator A5002973886 @default.
• W2802899563 creator A5004669792 @default.
• W2802899563 creator A5009582351 @default.
• W2802899563 creator A5014681663 @default.
• W2802899563 creator A5015695327 @default.
• W2802899563 creator A5019132479 @default.
• W2802899563 creator A5019331033 @default.
• W2802899563 creator A5021551402 @default.
• W2802899563 creator A5022477189 @default.
• W2802899563 creator A5023346936 @default.
• W2802899563 creator A5029777782 @default.
• W2802899563 creator A5037092952 @default.
• W2802899563 creator A5042749420 @default.
• W2802899563 creator A5048541532 @default.
• W2802899563 creator A5053263729 @default.
• W2802899563 creator A5053307625 @default.
• W2802899563 creator A5062108383 @default.
• W2802899563 creator A5062397416 @default.
• W2802899563 creator A5062969443 @default.
• W2802899563 creator A5064203357 @default.
• W2802899563 creator A5064292088 @default.
• W2802899563 creator A5064884168 @default.
• W2802899563 creator A5066241274 @default.
• W2802899563 creator A5066945456 @default.
• W2802899563 creator A5067271492 @default.
• W2802899563 creator A5069174478 @default.
• W2802899563 creator A5071418777 @default.
• W2802899563 creator A5074019658 @default.
• W2802899563 creator A5083920381 @default.
• W2802899563 creator A5086661060 @default.
• W2802899563 creator A5086957919 @default.
• W2802899563 date "2018-07-01" @default.
• W2802899563 modified "2023-10-14" @default.
• W2802899563 title "Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer" @default.
• W2802899563 cites W1864574802 @default.
• W2802899563 cites W1870673602 @default.
• W2802899563 cites W1893588230 @default.
• W2802899563 cites W1902718972 @default.
• W2802899563 cites W1965151932 @default.
• W2802899563 cites W1975918912 @default.
• W2802899563 cites W1985213644 @default.
• W2802899563 cites W2012852529 @default.
• W2802899563 cites W2015943054 @default.
• W2802899563 cites W2019106289 @default.
• W2802899563 cites W2068523052 @default.
• W2802899563 cites W2073804272 @default.
• W2802899563 cites W2081162953 @default.
• W2802899563 cites W2082821677 @default.
• W2802899563 cites W2094929011 @default.
• W2802899563 cites W2097749048 @default.
• W2802899563 cites W2098028863 @default.
• W2802899563 cites W2101562875 @default.
• W2802899563 cites W2103561213 @default.
• W2802899563 cites W2103818040 @default.
• W2802899563 cites W2107575831 @default.
• W2802899563 cites W2113382133 @default.
• W2802899563 cites W2114788594 @default.
• W2802899563 cites W2122503228 @default.
• W2802899563 cites W2123086444 @default.
• W2802899563 cites W2128042367 @default.
• W2802899563 cites W2131178190 @default.
• W2802899563 cites W2140310677 @default.
• W2802899563 cites W2143934748 @default.
• W2802899563 cites W2160107406 @default.
• W2802899563 cites W2164791945 @default.
• W2802899563 cites W223909586 @default.
• W2802899563 cites W2303680209 @default.
• W2802899563 cites W2312132282 @default.
• W2802899563 cites W2343368549 @default.
• W2802899563 cites W2589769928 @default.
• W2802899563 cites W2597872842 @default.
• W2802899563 cites W2599294066 @default.
• W2802899563 doi "https://doi.org/10.1200/jco.2017.75.0158" @default.
• W2802899563 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6049398" @default.
• W2802899563 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29742009" @default.
• W2802899563 hasPublicationYear "2018" @default.
• W2802899563 type Work @default.
• W2802899563 sameAs 2802899563 @default.
• W2802899563 citedByCount "101" @default.
• W2802899563 countsByYear W28028995632018 @default.
• W2802899563 countsByYear W28028995632019 @default.
• W2802899563 countsByYear W28028995632020 @default.
• W2802899563 countsByYear W28028995632021 @default.
• W2802899563 countsByYear W28028995632022 @default.
• W2802899563 countsByYear W28028995632023 @default.
• W2802899563 crossrefType "journal-article" @default.
• W2802899563 hasAuthorship W2802899563A5002973886 @default.
• W2802899563 hasAuthorship W2802899563A5004669792 @default.
• W2802899563 hasAuthorship W2802899563A5009582351 @default.
• W2802899563 hasAuthorship W2802899563A5014681663 @default.
• W2802899563 hasAuthorship W2802899563A5015695327 @default.
• W2802899563 hasAuthorship W2802899563A5019132479 @default.
• W2802899563 hasAuthorship W2802899563A5019331033 @default.
• W2802899563 hasAuthorship W2802899563A5021551402 @default.
• W2802899563 hasAuthorship W2802899563A5022477189 @default.
• W2802899563 hasAuthorship W2802899563A5023346936 @default.

• next